Events
-
-
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
ASCO 2026: Phase 3 PEAK study could usher in new second-line therapy for GIST
-
ASCO 2026: Personalised vaccine boosts immune activity against brain cancer
-
ASCO 2026: GLP-1s may reduce metastatic progression of certain obesity-related cancers
-
ASCO 2026: Yoga may help cancer survivors sleep better and reduce anxiety, fatigue
-
-
Astronauts may be at risk for heart disease and cancer-causing mutations
Astronauts are at higher risk for developing mutations—possibly linked to spaceflight—that can increase the risk…
Considering genetic risk in prostate cancer referrals could lead to earlier diagnosis
Men at the highest risk for prostate cancer could be fast-tracked for investigation if their…
Can exercise boost chemotherapy’s effectiveness, improve outlook for colon cancer survivors?
Two new US studies will recruit more than 300 patients with colon cancer to determine…
New clues about why some metastatic prostate cancers don’t respond to enzalutamide
- Immune system could be key to reducing the growth of prostate cancer spread to the bone
- The Oncology Podcast: Improving Identification of Aggressive versus Slow Growing Prostate Cancer with Associate Professor Matt Naylor
- Immunotherapy effective in metastatic prostate cancers with specific markers of immune activation
Personalised treatment benefits kidney cancer patients
Personalised treatment plans may extend life expectancy for early-stage kidney cancer patients who have risk factors for worsening kidney disease,…
JOIN THE ONCOLOGY NETWORK
If you would like even more free news articles, access to our exclusive HCP only content including the latest podcasts from The Oncology Podcast and our Industry Partner Podcasts (including links to all papers and show notes), along with all our other resources, head over to The Oncology Network and sign up - FREE forever for HCPs only.